Selective intraarterial chemoradiation therapy for oropharyngeal carcinoma with high-dose cisplatin
- First Online:
- Cite this article as:
- Nishio, R., Saito, K., Ito, H. et al. Jpn J Radiol (2011) 29: 570. doi:10.1007/s11604-011-0599-1
- 113 Downloads
Cisplatin has shown a high tumor response rate among head and neck carcinomas, and the tumor response is related to the cisplatin dosage. The purpose of this study was to evaluate the efficacy and toxicity of selective intraarterial chemoradiation therapy for oropharyngeal carcinomas with high-dose cisplatin.
Materials and methods
This retrospective study consisted of 21 patients with oropharyngeal carcinoma, stages II-IVB, in whom intraarterial chemoradiation therapy was performed between 2000 and 2008. All patients were given two courses of selective intraarterial infusions of cisplatin (300 mg/m2), systemic chemotherapy with 5-fluorouracil, and simultaneous radiation therapy (58–61 Gy/30 fractions), with a 1-week rest period.
The 2-year overall survival rate of the 15 patients who completed the therapeutic regimen was 71.3%. The 2-year locoregional control rate and disease-free survival rate were 95.0% and 67.7%, respectively.
Selective intraarterial high-dose cisplatin chemotherapy with concomitant radiation therapy shows results similar to those of original methods in terms of survival and locoregional control with a reduction in the number of procedure times.